Key points
- Enhanced control and readout of the 12CQ quantum project
- Improved quantum spin coherence lifetimes and manufacturability
- Launched bespoke Tunnelling Magnetoresistance (TMR) sensors for industrial applications
Full summary
Archer has made significant progress on its 12CQ quantum project, Biochip technology, and launched bespoke Tunnelling Magnetoresistance (TMR) sensors for industrial applications. For the 12CQ quantum project, the company enhanced control (input of data) and readout (output of data) capabilities, extended quantum spin coherence lifetimes, and improved manufacturability. Archer also launched TMR sensors that leverage quantum phenomena to detect subtle magnetic field changes, aiming to provide performance advantages for applications in AI, data centres, automotive, and IoT. In the Biochip development, Archer initiated experiments targeting chronic kidney disease detection using its graphene field-effect transistor (gFET) sensor, moved closer to feasibility stages, and improved testing accuracy. The company also enhanced the gFET's scalability, performance, and CMOS integration through a multi-project wafer run. Archer continues to strengthen its technical team and grow under its updated corporate strategy to accelerate the commercialisation of its technologies, supported by a strong cash position of $16.8 million.
Outlook
Archer will continue to progress the development and commercialisation of its 12CQ quantum, TMR sensor, and Biochip technologies, leveraging its technical expertise, global partnerships, and strong financial position.